Analyst rates Greenwich LifeSciences, Inc., a Buy: open-label data showed 70%-80% lower recurrence in 250 non-HLA-A*02 patients, backing Phase 3 expansion.
Rising rates raise the bar for risky science. Meet three clinical-stage cancer stocks with pristine, debt-free balance sheets, plus the screener that surfaces the rest.
This is the newest page. Registered accounts read further back.